Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2007-06-12
2007-06-12
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S184100, C424S247100
Reexamination Certificate
active
10918845
ABSTRACT:
Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In certain embodiments, the neurotoxins are obtained fromClostridium botulinum.
REFERENCES:
patent: 5158976 (1992-10-01), Rosenberg
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5548661 (1996-08-01), Price et al.
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5856665 (1999-01-01), Price et al.
patent: 6143306 (2000-11-01), Donovan
patent: 6235289 (2001-05-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6416765 (2002-07-01), Donovan
patent: 6416959 (2002-07-01), Giuliano et al.
patent: 6429189 (2002-08-01), Borodic
patent: 2003/0032069 (2003-02-01), Muraca
patent: 9903483 (1999-01-01), None
Adler, M et al, Toxicon, vol. 39, pp. 233-243, 2001.
Aoki, K. Roger, European J. of Neurology, vol. 6(suppl. 4), pp. S3-S10, 1999.
Borodic, Gary E. et al, Ophthalmic Plastic and Reconstructive Surgery, vol. 9(3), pp. 182-190.
Dodd, SL et al, Eur. J. Neurol., Mar. 1998, vol. 5(2) pp. 181-186.
Duchen, LW, J. of Neurological Sciences, pp. 47-74, 1971, vol. 14(1).
Inagi, K et al, The Laryngoscope, vol. 108 (7), Jul. 1998, pp. 1055-1061.
Tang, Xiaofu et al, Chinese Medical Journal, 2000, vol. 113(9), pp. 794-798.
Sampaio, C et al, Movement Disorders, vol. 12(6), pp. 1013-1018, 1997.
Aoki, K.R.,Preclinical update on Botox®(botulinum toxin type A)—purified neurotoxin complex relative to other botulinum neurotoxin preparations, European Journal of Neurology 1999, 6 (suppl 4):S3-S10.
Barry, B.W.,Novel mechanisms and devices to enable successful transdermal drug delivery, European Journal of Pharmaceutical Sciences, 14 (2001) 101-114.
Bigalke, H., et al.,Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal court neurons in culture, Brain Res. 1985;360:318-24.
Bigalke, H. et al.,Tetanus toxin and botulinum A toxin inhibit release and uptake of carious transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn Schmiedebergs Arch Pharmocol, 1981:316-244-51.
Boyd, R.S., et al.,The insulin secreting -cell line. HIT-15 contains SNAP-25 which is a target for botulinum neurotoxin-A, Movement Disorders, vol. 10, No. 3, 1995, pp. 376.
Garcia, A., et al.,Cosmetic denervation of the muscles of facial expression with botulinum toxin, Dermatol Surg 1996, 22: pp. 39-43.
Gonelle-Gispert, C., et al., SNAP-25a and 25bisoforms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem. J. (1999) 339, 159-165.
Habermann, E., et al., Tetanus toxin and botulinum A anc C neurotoxins inhibit noradrenaline release from cultured mouse brain, J. of Neurochemistry, 51, 522-527 (1988).
Habermann, E.,Inhibition byb tetanus and botulinum A toxin of the release of [3H ]noradrenaline and [3H ] GABA from rat brain homogenate, Experientia 1988 Mar 15:44(3):224-6.
Jankovic, J. et al.,Therapy with Botulinum Toxin, Marcel Dekker, Inc., 1994, p. 5.
Li, F., et al.,Formation of binucleated cardiac myocytes in rat heart II. Cytoskeletal organization, J. Mol Cell Cardiolo 29, 1553-1565 (1997).
Lim, D.A., et al.,Interaction between astrocytes and adult subventricular zone precursors stimulates neurogenesis, Proc. Natl. Acad. Sci. USA, vol. 96, pp. 7256-7531, Jun. 1999, Neurobiology.
Luna, L.E.,Manual of histologic staining methods of the armed forces institute of pathology. 3rded., 1968 Chapter 6, McGraw-Hill, pp. 72-99.
Manual of Histologic and Special Staining Technics, McGraw-Hill Book Co., The Blakiston Division 2ndEd., (1960) Chp. 6,Stains for Connective Tissue, pp. 55-95.
Marchese-Ragona, R., et al.,Management of Parotid Sialocele with Botulinum Toxin, The Laryngoscope, Aug. 1999, 109, pp. 1344-1346.
Marjarma-Lyons, et al.,Tremor-predominant Parkinson's disease, Drugs and Aging Apr. 2000 16(4):273-278.
Naumann, M., et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European Journal of Neurology, 1999 6 (suppl 4): S111-S115.
Pearce, L.B., et al.,Pharmacologic characterization of botulinum toxin for basic science and medicine, Toxicon, 1997 vol. 35, No. 9, pp. 1373-1412.
Pearce, L.B., et al.,Measurement of botulinum toxin activity: evaluation of the lethality assay, Toxicology and Applied Pharmacology 128, 69-77 (1994).
Sesardic, D., et al.,Refinement and validation of an alternative bioassay for potency testing of therapeutic botulimun type A toxin, Pharmacol Toxicol 1996; 78(5): 283-8.
Sanchez-Prieto, J., et al.,Botulinum toxin A blocks A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes, Eur J. Biochem Jun. 1987 165(3):675-681.
Schantz, E., et al.Standardized assay for chlostridium botulinum toxins, J. Assoc of Anal Chem. 1978;61(1)pp. 96-9.
Schantz, E., et al.,Properties and use of botulinum toxin and other microbial neurotoxins in medicine, Microbiological Reviews, Mar. 1992 p. 80-99, vol. 56, No. 1.
Singh, B.R.,Critical aspects of bacterial protein toxins, Natural Toxins II, 1996 Plenum Press, NY, Chp. 4, pp. 63-84.
Voytik, S.L., et al.,Differential expression of muscle regulatory factor genes in normal and denervated adult rat hind limb muscles, Developmental Dynamics (1993) 198:214-224.
Adler, M., et al.,Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle, Toxicon 39 (2001) 233-243.
Hamjian, J.A., et al., Abstract:Serial neurophysiological studies of intramuscular botulinum A toxin in humans, Database Medline PubMed ID: 7969239, Dec. 1994 (1994012).
Hogwei, D., et al.,Morphologic changes in extraocular muscles after injection botilinum A toxin, Chin Ophthal Res. Apr. 2000, vol. 18, No. 2, pp. 140-142.
Pinter, M.J.,Axotomy-like changes in cat motoneuron electrical properties elicited by botulinum toxin depend on the complete elimination of neuromuscular transmission, Journal of Neuroscience, Mar. 1991, 11(3): pp. 657-666.
Samuel, D.P.,Hemihypertrophy and a poorly differentiated embryonal rhabdomyosarcoma of the pelvis, Medical and Pediatric Oncology 32:38-43 (1999).
Braun, T., et al.,Differential expression of myogenic determination genes in muscle cells: possible autoactivation by the Myf gene products, EMBO Journal, vol. 8, #12 pp. 3617-3625, 1989.
Chomcczynski, P., et al.,Single-step method of RNA isolation by acid guanidinium thioyanate-phenol-chloroform extraction, Analytical Biochemistry 162, 156-159 (1987).
David, R.L., et al.,Expression of a single transfected cDNA converts fibroblasts to myoblasts, Cell, vol. 51, 978-1000, Dec. 24, 1987.
Koppe, R.I., et al.,cDNA clone and expression analysis of rodent fast and slow skeletal muscle troponin I mRNAs*, The Journal of Biological Chemistry, vol. 264, No. 24, Aug. 25, 1989 pp. 14327-14333.
Lehrach, H. , et al.,RNA molecular weight determinations by gel electrophoresis under denaturing conditions, a critical reexamination, Biochemistry, vol. 16, No. 21, 1977, pp. 4743-4751.
Wright, W.E., et al.,Myogenin, a factor regulating myogenesis, has a domain homologous to MyoD, Cell, vol. 56, Feb. 24, 1989, pp. 607-617.
Ansved, T. Neurology, (United States) May 1997, vol. 48(5), pp. 1440-1442, Muscle fiber atropy in leg muscles after botulinum toxin type A treatment of cervical dystonia.
Bhatia, KP et al, J. Neurol. Neurosurg. Psychiatry, 1999, vol. 67, pp. 90-93.
Borodic et al., 1992, Botulinum and Tetanus Neurotoxins (ed BR DasGupta, Plenum Press, New York) pp. 623-645.
Chen, Chen-Ming et al., J. Appl. Physiol. vol. 93, pp. 1437-1447, Jun. 30, 2002.
Coffield, J.A. et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 289, No. 3, pp. 1509-1516, 1999.
Doggweiler, R.
Chow Edward
Holland James M.
Allergan Inc.
Donovan Stephen
Nassif Claude L.
Navarro Mark
Portner Ginny Allen
LandOfFree
Nuclei density and nuclei area methods for determining... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nuclei density and nuclei area methods for determining..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nuclei density and nuclei area methods for determining... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3839070